WebApr 11, 2014 · B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance Inflammation and metabolism have been shown to be evolutionary linked and increasing evidence exists that pro-inflammatory factors are involved in the pathogenesis of obesity and type 2 diabetes. Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. The most … See more Belimumab is indicated for the treatment of active systemic lupus erythematosus and active lupus nephritis. See more B lymphocytes (B cells), which are part of the normal immune response, are also responsible for the over-aggressive response seen in autoimmune diseases like systemic lupus erythematosus. B cells develop in the bone marrow and continue to mature peripherally … See more Legal status Under the brand name Benlysta, belimumab received FDA approval for the treatment of systemic lupus erythematosus on 9 … See more • "Belimumab". Drug Information Portal. U.S. National Library of Medicine. See more Common adverse effects reported with belimumab include nausea, diarrhea, and fever, as well as hypersensitivity and infusion-site reactions, which were severe in 0.9% of patients. … See more B-cell activating factor is a naturally occurring protein that was discovered by researchers from National Jewish Health (previously the National Jewish Medical and Research … See more Blisibimod, an inhibitor of both soluble and membrane-bound BAFF, has demonstrated similar reductions of B cells in clinical trials and is being investigated in a Phase II clinical … See more

An APRIL to remember: novel TNF ligands as therapeutic targets

WebApr 15, 2024 · It is classified as a B-lymphocyte stimulator (BLyS)-specific inhibitor. Saphnelo targets the type I interferon receptor and inhibits the activity of type 1 … WebIdentifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data dr howton colorado

Pharmacokinetic Characteristics, Safety, and Tolerability …

WebAtacicept as the inhibitor of BLyS and APRIL thus has a broader biological effect than belimumab alone and more clearly blocks B-cell maturation and B-cell and plasma cell … WebB lymphocyte stimulator (BLyS), a protein discovered in the 1990s that induces B cell prolif-eration and differentiation, promotes B cell survival, and is important in immunoglobulin ... human SLE provided sufficient evidence to support the use of an inhibitor of BLyS as a novel therapy to reduce SLE disease activity. Progressing from phase I ... WebNational Center for Biotechnology Information dr howzean dizay